Dear EURETINA Members, A very warm welcome to the July 24th, 2024 edition of EURETINA’s web-based digital periodical, “EURETINA Brief”. EURETINA are delighted to continue… Read More »July 24th, 2024 “EURETINA-Brief”© Issue No. 296
Researchers at the School of Pharmacy, University of Eastern Finland, and the Gavin Herbert Eye Institute-Center for Translational Vision Research, Department of Ophthalmology, University of… Read More »Re-purposed drugs for retinitis pigmentosa may address mutation-independent approach for retinal degenerations.
Researchers at UCL Institute of Ophthalmology, University College London, and Moorfields Eye Hospital, have reported a detailed natural history, retinal imaging dataset and clinical features… Read More »A first in-depth retrospective longitudinal study of Usher syndrome on USH1D, providing key natural history, image data and clinical features.
A private biotech company, Beacon Therapeutics, based in London, UK (and Florida and Cambridge, USA), has received an investment of $170M from several funding partners,… Read More »Beacon Therapeutics has announced an investment of $170M for the development of ophthalmic gene therapies.
According to the Royal College of Ophthalmologists, the term of “low vision” is not defined in UK legislation however, the UK Low Vision Services Consensus… Read More »Book Review of Low Vision-Principles and Management, 1st edition (Elsevier); by Christine Dickinson, Ana Hernandez Trillo and Michael Crossland
Researchers based at the MRC Human Genetics Unit, at the University of Edinburgh, and the Western General Hospital (Edinburgh), have reported a new study indicating… Read More »X-linked retinitis pigmentosa (XLRP) due to RPGR variants report new data on actin dynamics.
The expansion on the field of genetics and genomics is reflective to the changes of the average 6.4 years between each of the nine editions… Read More »Book Review of Thompson & Thompson’s Genetics and Genomics in Medicine, 9th edition (Elsevier).
